• INTEGRATIVE "MULTI-OMICS" AND FUNCTIONAL PLATFORM FOR THE COMPLETE DIAGNOSTIC CHARACTERIZATION OF TUMORS: THE ITALIAN TUMOR CHEMOGENOMIC PROFILER (IT-TCP)

  NCT07403630

  RecruitingInterventionalNot ApplicableUpdated Feb 17, 2026
• Advancing Chemical and Genomic Strategies for Relapsed/Refractory T-ALL and ETP-ALL

  NCT04582487

  Unknown statusInterventionalNot ApplicableUpdated Feb 7, 2024
• Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia

  NCT00900224

  Unknown statusObservationalUpdated Aug 31, 2023
• ChEmo-Genomics Based Treatment of Acute Myeloid Leukemia

  NCT02619071

  Unknown statusInterventionalNot ApplicableUpdated Jun 28, 2016
• Liquid Micro-biopsy: a Novel Approach to Study Tumor Microenvironment From the Peripheral Blood

  NCT06764589

  Active, not recruitingObservationalUpdated Jan 8, 2025
• The Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias

  NCT05756322

  RecruitingInterventionalPhase 1Phase 2Updated Mar 27, 2026

ClinicalTrials.gov ID

NCT06626893

Lead Sponsor

Azienda Ospedaliero-Universitaria di ParmaOTHER

Overall Status

Recruiting

Study Type

Interventional

Phase

Not Applicable

Enrollment

100Estimated

Last Update Posted

Oct 4, 2024Actual

Start Date

Mar 1, 2022Actual

Primary Completion Date

Mar 1, 2025Estimated

Completion Date

Mar 1, 2025Estimated

Official Title

Integrative "Omics" Approaches for Leukemia Target Identification and Matched Therapeutic Intervention

Brief Summary

The goal of this clinical trial is to use multiple "omics" sciences to more thoroughly investigate Acute Recurrent/Refractory Leukemias (LA R/R) after conventional therapy in order to identify new targets and/or therapeutic approaches, in patients with a diagnosis of Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma B(ALL-B), Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma T (ALL-T), Acute Biphenotypic Leukemia/II as defined by WHO( World Health Organization) 2016, relapsed or refractory after at least one line of therapy. The main question that the trial aims to answer is: "Can molecules with known biological activity be active and represent possible new therapeutic strategies in relapsed/refractory Acute Leukemias on the basis of response profiles identified through the integration of next-generation chemogenomic and functional analyses? " It is expected that a minimum of 100 patients, male and female, aged 18 years and older, will be included. To participate in the study, the patient must consent to the performance on biological specimen (peripheral blood and bone marrow) of genetic/molecular and/or "omics" investigations performed with modern sequencing techniques, such as Next Generation Sequencing, Single Cell RNA Seq (scRNAseq), RT-qPCR(Quantitative reverse transcription polymerase chain reaction). These investigations will aim to improve the understanding of the genetic and molecular alterations of her disease. In addition, your cells will be used in the laboratory to perform in vitro sensitivity studies (drug response profiling - DRP) that aim to simultaneously test a set of hundreds of drugs to assess sensitivity or resistance profiles of your disease cells with the aim of identifying specific new therapies that target specific cellular mechanisms. In addition, part of the biological sample will be used for investigations of the bone marrow microenvironment and the "secretome", i.e., cell signaling molecules and methods. In order to accomplish this study, samples from peripheral or bone marrow blood taken during routine investigations performed during follow-up and re-evaluation visits for the patient's disease as per normal clinical practice will be used. Among the investigations that will be performed on the blood sample will be the genetic/molecular and/or omics and preclinical investigations described above.

• Myeloid Leukemia, Acute
• Leukemia, Acute Lymphoblastic

• Functional tests
• Next Generation Sequencing analysis
• Microvesicles analysis

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Patients to be enrolled in the study must have a diagnosis of AML, B ALL/LBL, T ALL/LBL, MPAL/AUL as described by WHO 2016 classification and must complained relapsed or refractory disease after at least one line of therapy
• Ages Eligible for Study: over 18years
• Patients must have greater than 5% blasts in the bone marrow with or without extramedullary disease
• Patients with must have recurrent disease, documented by clinical or radiographic criteria, as well as histologic verification of the malignancy at original diagnosis
• Patients may be enrolled on study regardless of the timing of prior I therapy
• Patients must be capable of understanding the investigational nature and the objectives of the study. All patients must sign a written informed consent.

Exclusion Criteria:

-

Primary Purpose

Basic Science

Allocation

N/A

Interventional Model

Single Group Assignment

Masking

None (Open Label)

Lead Sponsor

Azienda Ospedaliero-Universitaria di ParmaOTHER

bcambo@ao.pr.it0521 704446